ASTELLAS PHARMA
π―π΅Japan
- Country
- π―π΅Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
Long-term Treatment Study of CDP870 Self-injection in Patients With Active Rheumatoid Arthritis Who Are Participating in the Long-term Treatment Studies (Study 275-08-002 or Study 275-08-004) of CDP870
- First Posted Date
- 2015-10-26
- Last Posted Date
- 2015-11-16
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 86
- Registration Number
- NCT02586246
Specified Drug Use-results Survey of Betanis Tablets for Patients With Coexisting Cardiovascular Disease
- First Posted Date
- 2015-10-07
- Last Posted Date
- 2015-10-07
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 316
- Registration Number
- NCT02570035
- Locations
- π―π΅
Site JP81013, Aichi, Japan
π―π΅Site JP81014, Aichi, Japan
π―π΅Site JP81005, Chiba, Japan
Bioequivalence Evaluation of a New and Current Tablet of ASP015K
- First Posted Date
- 2015-08-24
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 40
- Registration Number
- NCT02531191
A Study of ASP1585 to Evaluate the Bioequivalence Between ASP1585 Granules and ASP1585 Capsules
- First Posted Date
- 2015-08-24
- Last Posted Date
- 2015-08-24
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 60
- Registration Number
- NCT02531204
Pharmacodynamics, Pharmacokinetics, and Safety of ASP1941 in Patients With Type 1 Diabetes Mellitus
- First Posted Date
- 2015-08-20
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 43
- Registration Number
- NCT02529449
- Locations
- π―π΅
Site JP00006, Aichi, Japan
π―π΅Site JP00002, Fukuoka, Japan
π―π΅Site JP00009, Gunma, Japan
Single and Multiple Dosing Study in Hemodialysis Patients With Hyperphosphatemia in Japan
Phase 1
Completed
- Conditions
- Chronic Kidney DiseaseHyperphosphatemia Undergoing Hemodialysis
- Interventions
- First Posted Date
- 2015-07-29
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24
- Registration Number
- NCT02510274
- Locations
- π―π΅
Site: 4, Aichi, Japan
π―π΅Site: 5, Aichi, Japan
π―π΅Site: 1, Ibaraki, Japan
A Single and Multiple Oral Dose Study and a Treatment Schedule-finding Study in Non-elderly, Healthy Subjects
Phase 1
Completed
- Conditions
- Pharmacokinetics of ASP3325 in Non-elderly, Healthy Adult Japanese Male and Female, and Caucasian Male Subjects
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-07-17
- Last Posted Date
- 2015-07-17
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 124
- Registration Number
- NCT02500953
A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-NaΓ―ve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations
Phase 2
Terminated
- Conditions
- EGFR-TKI-naΓ―ve Patients With NSCLC Harboring EGFR Activating Mutations
- Interventions
- Drug: ASP8273 CapsulesDrug: ASP8273 Capsules A
- First Posted Date
- 2015-07-17
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 31
- Registration Number
- NCT02500927
- Locations
- π―π΅
Site: 5, Fukuoka, Japan
π―π΅Site: 9, Hiroshima, Japan
π―π΅Site: 8, Hyogo, Japan
Specified Drug Use Results Survey of Ipragliflozin Treatment in type2 Diabetes Patients
- First Posted Date
- 2015-06-24
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 11412
- Registration Number
- NCT02479399
A Study of ASP4070 to Confirm Safety and Immunological Response in Patients With Pollen Allergy
- First Posted Date
- 2015-06-11
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 66
- Registration Number
- NCT02469688